Didanosine is a nucleoside analog reverse transcriptase inhibitor used in AIDS treatment. HIV infected people has to be polymedicated for the rest of their life, at least at present. Therefore, it is of great interest to carry out extensive investigations in this field, aimed not only to find new and more powerful drugs but also, and not less important, to develop more effective formulations of already known drugs. Controlled-released dosage forms are systems studied for obtaining a therapeutically effective concentration of drug in the systemic circulation fro a prolonged time, thus achieving better patient compliance and making to be possible a reduction of the total dose of drug administered and of side effects appearance [1]. In the context of a wide research project for the development of controlled-release matrix tablets of didanosine [2, 3], the aim of this work was to study the influence of varying the ratio between Eudragit RS PM (an acrylic acid-derived resin) and Ethocel 100 (an ethylcellulose), selected as components of the polymeric matrix, on the drug release behaviour, keeping constant both the drug content and the total weight of the tablets, as well the granulometric fraction of the polymers. Another objective was to study the influence of variations of the drug/polymeric matrix ratio, keeping constant the ratio between the two polymers and the total weight of the tablets.
INFLUENCE OF FORMULATION VARIABLES ON DIDANOSINE RELEASE FROM MATRICES CONTAINING EUDRAGIT RS-PM AND ETHOCEL 100 / Sànchez-Lafuente C.; Faucci M.T.; Fernàndez-Arévalo, M.; Alvarez-Fuentes, J.; Rabasco, A.M; Mura, P.. - STAMPA. - (2000), pp. 219-220. (Intervento presentato al convegno 3rd world meeting on pharmaceutics, biopharmaceutics, pharmaceutical technology tenutosi a Berlin nel April 03-06, 2000).
INFLUENCE OF FORMULATION VARIABLES ON DIDANOSINE RELEASE FROM MATRICES CONTAINING EUDRAGIT RS-PM AND ETHOCEL 100
FAUCCI, MARIA TERESA;MURA, PAOLA ANGELA
2000
Abstract
Didanosine is a nucleoside analog reverse transcriptase inhibitor used in AIDS treatment. HIV infected people has to be polymedicated for the rest of their life, at least at present. Therefore, it is of great interest to carry out extensive investigations in this field, aimed not only to find new and more powerful drugs but also, and not less important, to develop more effective formulations of already known drugs. Controlled-released dosage forms are systems studied for obtaining a therapeutically effective concentration of drug in the systemic circulation fro a prolonged time, thus achieving better patient compliance and making to be possible a reduction of the total dose of drug administered and of side effects appearance [1]. In the context of a wide research project for the development of controlled-release matrix tablets of didanosine [2, 3], the aim of this work was to study the influence of varying the ratio between Eudragit RS PM (an acrylic acid-derived resin) and Ethocel 100 (an ethylcellulose), selected as components of the polymeric matrix, on the drug release behaviour, keeping constant both the drug content and the total weight of the tablets, as well the granulometric fraction of the polymers. Another objective was to study the influence of variations of the drug/polymeric matrix ratio, keeping constant the ratio between the two polymers and the total weight of the tablets.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
